Changchun High & New Technology Industries Group Inc (000661) - Net Assets
Based on the latest financial reports, Changchun High & New Technology Industries Group Inc (000661) has net assets worth CN¥25.14 Billion CNY (≈ $3.68 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥30.77 Billion ≈ $4.50 Billion USD) and total liabilities (CN¥5.63 Billion ≈ $824.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000661 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥25.14 Billion |
| % of Total Assets | 81.7% |
| Annual Growth Rate | 17.48% |
| 5-Year Change | 44.28% |
| 10-Year Change | 458.81% |
| Growth Volatility | 27.04 |
Changchun High & New Technology Industries Group Inc - Net Assets Trend (1993–2025)
This chart illustrates how Changchun High & New Technology Industries Group Inc's net assets have evolved over time, based on quarterly financial data. See Changchun High & New Technology Industri defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Changchun High & New Technology Industries Group Inc (1993–2025)
The table below shows the annual net assets of Changchun High & New Technology Industries Group Inc from 1993 to 2025. For live valuation and market cap data, see 000661 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥24.87 Billion ≈ $3.64 Billion |
-4.72% |
| 2024-12-31 | CN¥26.10 Billion ≈ $3.82 Billion |
+4.28% |
| 2023-12-31 | CN¥25.03 Billion ≈ $3.66 Billion |
+20.32% |
| 2022-12-31 | CN¥20.81 Billion ≈ $3.04 Billion |
+20.70% |
| 2021-12-31 | CN¥17.24 Billion ≈ $2.52 Billion |
+39.87% |
| 2020-12-31 | CN¥12.32 Billion ≈ $1.80 Billion |
+39.92% |
| 2019-12-31 | CN¥8.81 Billion ≈ $1.29 Billion |
+38.87% |
| 2018-12-31 | CN¥6.34 Billion ≈ $928.06 Million |
+21.96% |
| 2017-12-31 | CN¥5.20 Billion ≈ $760.97 Million |
+16.85% |
| 2016-12-31 | CN¥4.45 Billion ≈ $651.24 Million |
+82.76% |
| 2015-12-31 | CN¥2.44 Billion ≈ $356.34 Million |
+19.10% |
| 2014-12-31 | CN¥2.04 Billion ≈ $299.19 Million |
+20.06% |
| 2013-12-31 | CN¥1.70 Billion ≈ $249.19 Million |
+30.61% |
| 2012-12-31 | CN¥1.30 Billion ≈ $190.80 Million |
+37.80% |
| 2011-12-31 | CN¥946.20 Million ≈ $138.46 Million |
+17.70% |
| 2010-12-31 | CN¥803.92 Million ≈ $117.64 Million |
+16.35% |
| 2009-12-31 | CN¥690.94 Million ≈ $101.11 Million |
+20.91% |
| 2008-12-31 | CN¥571.43 Million ≈ $83.62 Million |
+14.88% |
| 2007-12-31 | CN¥497.44 Million ≈ $72.79 Million |
+1.83% |
| 2006-12-31 | CN¥488.51 Million ≈ $71.49 Million |
+16.83% |
| 2005-12-31 | CN¥418.13 Million ≈ $61.19 Million |
-8.05% |
| 2004-12-31 | CN¥454.72 Million ≈ $66.54 Million |
+1.84% |
| 2003-12-31 | CN¥446.52 Million ≈ $65.34 Million |
-21.65% |
| 2002-12-31 | CN¥569.90 Million ≈ $83.39 Million |
-0.95% |
| 2001-12-31 | CN¥575.37 Million ≈ $84.20 Million |
+2.76% |
| 2000-12-31 | CN¥559.91 Million ≈ $81.93 Million |
-28.97% |
| 1999-12-31 | CN¥788.30 Million ≈ $115.35 Million |
+3.28% |
| 1998-12-31 | CN¥763.27 Million ≈ $111.69 Million |
+69.23% |
| 1997-12-31 | CN¥451.02 Million ≈ $66.00 Million |
+27.44% |
| 1996-12-31 | CN¥353.90 Million ≈ $51.79 Million |
+106.32% |
| 1995-12-31 | CN¥171.53 Million ≈ $25.10 Million |
+20.48% |
| 1994-12-31 | CN¥142.38 Million ≈ $20.83 Million |
-0.83% |
| 1993-12-31 | CN¥143.57 Million ≈ $21.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Changchun High & New Technology Industries Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1625976934576.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥16.26 Billion | 73.88% |
| Other Components | CN¥5.75 Billion | 26.12% |
| Total Equity | CN¥22.01 Billion | 100.00% |
Changchun High & New Technology Industries Group Inc Competitors by Market Cap
The table below lists competitors of Changchun High & New Technology Industries Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Graham Holdings Co
NYSE:GHC
|
$3.83 Billion |
|
Huaihe Energy Group Co Ltd
SHG:600575
|
$3.83 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
$3.83 Billion |
|
First BanCorp.
NYSE:FBP
|
$3.83 Billion |
|
Shanghai Phichem Material Co Ltd Class A
SHE:300398
|
$3.82 Billion |
|
Cleanaway Waste Management Ltd
AU:CWY
|
$3.82 Billion |
|
JB Chemicals & Pharmaceuticals Limited
NSE:JBCHEPHARM
|
$3.82 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
$3.82 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Changchun High & New Technology Industries Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,999,514,866 to 22,008,558,120, a change of -990,956,746 (-4.3%).
- Net income of 154,971,453 contributed positively to equity growth.
- Dividend payments of 1,083,634,830 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥154.97 Million | +0.7% |
| Dividends Paid | CN¥1.08 Billion | -4.92% |
| Other Changes | CN¥-62.29 Million | -0.28% |
| Total Change | CN¥- | -4.31% |
Book Value vs Market Value Analysis
This analysis compares Changchun High & New Technology Industries Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 113.80x to 1.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.56 | CN¥64.10 | x |
| 1996-12-31 | CN¥1.16 | CN¥64.10 | x |
| 1997-12-31 | CN¥1.50 | CN¥64.10 | x |
| 1998-12-31 | CN¥2.22 | CN¥64.10 | x |
| 1999-12-31 | CN¥2.27 | CN¥64.10 | x |
| 2000-12-31 | CN¥1.48 | CN¥64.10 | x |
| 2001-12-31 | CN¥1.50 | CN¥64.10 | x |
| 2002-12-31 | CN¥1.51 | CN¥64.10 | x |
| 2003-12-31 | CN¥1.15 | CN¥64.10 | x |
| 2004-12-31 | CN¥1.15 | CN¥64.10 | x |
| 2005-12-31 | CN¥0.99 | CN¥64.10 | x |
| 2006-12-31 | CN¥1.06 | CN¥64.10 | x |
| 2007-12-31 | CN¥1.09 | CN¥64.10 | x |
| 2008-12-31 | CN¥1.18 | CN¥64.10 | x |
| 2009-12-31 | CN¥1.45 | CN¥64.10 | x |
| 2010-12-31 | CN¥1.74 | CN¥64.10 | x |
| 2011-12-31 | CN¥2.08 | CN¥64.10 | x |
| 2012-12-31 | CN¥3.08 | CN¥64.10 | x |
| 2013-12-31 | CN¥3.95 | CN¥64.10 | x |
| 2014-12-31 | CN¥4.84 | CN¥64.10 | x |
| 2015-12-31 | CN¥6.77 | CN¥64.10 | x |
| 2016-12-31 | CN¥11.46 | CN¥64.10 | x |
| 2017-12-31 | CN¥13.00 | CN¥64.10 | x |
| 2018-12-31 | CN¥15.61 | CN¥64.10 | x |
| 2019-12-31 | CN¥23.39 | CN¥64.10 | x |
| 2020-12-31 | CN¥26.77 | CN¥64.10 | x |
| 2021-12-31 | CN¥35.57 | CN¥64.10 | x |
| 2022-12-31 | CN¥44.29 | CN¥64.10 | x |
| 2023-12-31 | CN¥53.87 | CN¥64.10 | x |
| 2024-12-31 | CN¥57.16 | CN¥64.10 | x |
| 2025-12-31 | CN¥53.95 | CN¥64.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Changchun High & New Technology Industries Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.28%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.37x
- Recent ROE (0.70%) is below the historical average (11.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 15.90% | 19.89% | 0.26x | 3.03x | CN¥10.02 Million |
| 1996 | 15.99% | 39.69% | 0.19x | 2.10x | CN¥21.02 Million |
| 1997 | 11.10% | 38.44% | 0.15x | 1.94x | CN¥4.97 Million |
| 1998 | 10.65% | 27.49% | 0.20x | 1.94x | CN¥4.37 Million |
| 1999 | 2.03% | 4.56% | 0.23x | 1.97x | CN¥-54.57 Million |
| 2000 | 3.76% | 5.36% | 0.27x | 2.58x | CN¥-27.92 Million |
| 2001 | 0.96% | 1.07% | 0.32x | 2.79x | CN¥-40.79 Million |
| 2002 | 0.47% | 0.46% | 0.38x | 2.68x | CN¥-43.38 Million |
| 2003 | -31.17% | -25.50% | 0.27x | 4.47x | CN¥-142.87 Million |
| 2004 | 2.06% | 1.96% | 0.26x | 4.00x | CN¥-27.65 Million |
| 2005 | -19.69% | -12.09% | 0.34x | 4.73x | CN¥-88.76 Million |
| 2006 | 1.41% | 0.78% | 0.40x | 4.54x | CN¥-27.60 Million |
| 2007 | 2.28% | 1.14% | 0.44x | 4.59x | CN¥-25.40 Million |
| 2008 | 5.54% | 2.50% | 0.52x | 4.27x | CN¥-16.18 Million |
| 2009 | 16.80% | 7.15% | 0.66x | 3.56x | CN¥29.60 Million |
| 2010 | 16.56% | 7.42% | 0.66x | 3.37x | CN¥34.26 Million |
| 2011 | 17.40% | 8.46% | 0.63x | 3.27x | CN¥46.60 Million |
| 2012 | 32.26% | 17.02% | 0.76x | 2.49x | CN¥206.87 Million |
| 2013 | 23.81% | 13.86% | 0.73x | 2.36x | CN¥164.68 Million |
| 2014 | 21.79% | 14.06% | 0.72x | 2.16x | CN¥172.15 Million |
| 2015 | 21.63% | 16.01% | 0.63x | 2.15x | CN¥206.69 Million |
| 2016 | 12.43% | 16.73% | 0.47x | 1.59x | CN¥94.87 Million |
| 2017 | 14.96% | 16.14% | 0.56x | 1.66x | CN¥219.36 Million |
| 2018 | 18.96% | 18.73% | 0.57x | 1.78x | CN¥475.59 Million |
| 2019 | 21.96% | 24.07% | 0.58x | 1.57x | CN¥966.57 Million |
| 2020 | 27.87% | 35.52% | 0.51x | 1.55x | CN¥1.95 Billion |
| 2021 | 25.78% | 34.96% | 0.48x | 1.54x | CN¥2.30 Billion |
| 2022 | 22.94% | 32.79% | 0.49x | 1.44x | CN¥2.34 Billion |
| 2023 | 20.53% | 31.12% | 0.47x | 1.39x | CN¥2.32 Billion |
| 2024 | 11.23% | 19.18% | 0.43x | 1.35x | CN¥283.11 Million |
| 2025 | 0.70% | 1.28% | 0.40x | 1.37x | CN¥-2.05 Billion |
Industry Comparison
This section compares Changchun High & New Technology Industries Group Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Changchun High & New Technology Industries Group Inc (000661) | CN¥25.14 Billion | 15.90% | 0.22x | $3.83 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Changchun High & New Technology Industries Group Inc
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasa… Read more